N. Desai

发表

Annals of the New York Academy of Sciences Nanomedicines: Addressing the Scientific and Regulatory Gap

Y. Barenholz, G. Borchard, S. McNeil, 2022 .

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

Patrick Soon-Shiong, W. Gradishar, P. Soon-Shiong, 2008, Anti-cancer drugs.

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Patrick Soon-Shiong, Neil Desai, G. Hortobagyi, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I trial of ABI-007, nanoparticle paclitaxel, administered to patients with advanced non-hematologic malignancies.

D. V. Von Hoff, E. Hersh, N. Desai, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nanoparticle Albumin-Bound Anticancer Agents

N. Desai, 2015 .

Nab Technology : A Drug Delivery Platform Utilising Endothelial gp 60 Receptor-based Transport and Tumour-derived SPARC for Targeting I

N. Desai, I. Desai, 2009 .

Tissue response to intraperitoneal implants of polyethylene oxide-modified polyethylene terephthalate.

J. Hubbell, N. Desai, 1992, Biomaterials.

Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial

F. Meric-Bernstam, R. Kurzrock, A. González-Angulo, 2013, Clinical Cancer Research.

Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.

M. Flister, S. Ran, N. Desai, 2011, Neoplasia.

Abstract C246: nab®‐paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic cancer models

A. Maitra, M. Hidalgo, M. Rudek, 2009 .

SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab(B) for triple-negative metastatic breast cancer (TNMBC).

K. Blackwell, N. Desai, V. Trieu, 2010 .

SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC).

H. Rugo, R. Inhorn, D. Yardley, 2010 .

Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives.

D. Yardley, N. Desai, V. Trieu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol

P. Soon-Shiong, N. Desai, V. Trieu, 2005 .

601 Increased transport of nanoparticle albumin-bound paclitaxel (ABI-007) by endothelial gp60-mediated caveolar transcytosis: a pathway inhibited by Taxol

P. Soon-Shiong, N. Desai, V. Trieu, 2004 .

nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study

S. Loibl, N. Desai, J. Iglesias, 2010, Expert opinion on drug safety.

SPARC expression in head and neck cancer correlates with tumor response to nanoparticle albumin-bound paclitaxel (nab-paclitaxel, ABI-007, Abraxane)

P. Soon-Shiong, N. Desai, V. Trieu, 2006 .

Interpenetrating polymer networks of alginate and polyethylene glycol for encapsulation of islets of Langerhans.

P. Soon-Shiong, N. Desai, Z. Yao, 2000, Journal of microencapsulation.

SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study.

M. Hidalgo, R. Korn, M. Borad, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab-paclitaxel.

R. Inhorn, D. Yardley, N. Desai, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surface physical interpenetrating networks of poly(ethylene terephthalate) and poly(ethylene oxide) with biomedical applications

J. Hubbell, N. Desai, 1992 .

Phase I and Pharmacokinetic Study of ABI-007 , a Cremophor-free , Protein-stabilized , Nanoparticle Formulation of Paclitaxel 1

G. Hortobagyi, N. Ibrahim, R. Theriault, 2002 .

Avoidance of photoactivation in the epifluorescence video microscopic observation of thrombosis.

J. Hubbell, N. Desai, S. F. Hossiany, 1992, Journal of biomedical materials research.

The short-term blood biocompatibility of poly(hydroxyethyl methacrylate-co-methyl methacrylate) in an in vitro flow system measured by digital videomicroscopy.

J. Hubbell, N. Desai, 1989, Journal of biomaterials science. Polymer edition.

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

D. Kwiatkowski, R. Riedel, K. Ganjoo, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Solution technique to incorporate polyethylene oxide and other water-soluble polymers into surfaces of polymeric biomaterials.

J. Hubbell, N. Desai, J A Hubbell, 1991, Biomaterials.

Protein nanoparticles as drug carriers in clinical medicine.

Patrick Soon-Shiong, Neil Desai, P. Soon-Shiong, 2008, Advanced drug delivery reviews.

Endothelial Cell-Selective Materials for Tissue Engineering in the Vascular Graft Via a New Receptor

Jeffrey A. Hubbell, Neil P. Desai, Stephen P. Massia, 1991, Bio/Technology.

Biological responses to polyethylene oxide modified polyethylene terephthalate surfaces.

J. Hubbell, N. Desai, J A Hubbell, 1991, Journal of biomedical materials research.

Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel

Neil Desai, Alex Sparreboom, A. Sparreboom, 2008, Clinical Cancer Research.

Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

Michael Hawkins, Neil Desai, W. Gradishar, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

A. Maitra, M. Hidalgo, R. Korn, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges in Development of Nanoparticle-Based Therapeutics

N. Desai, 2012, The AAPS Journal.

SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients.

P. Soon-Shiong, N. Desai, V. Trieu, 2009, Translational oncology.

Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma

Kenneth C. Anderson, Kishan Patel, Shireen Vali, 2010, Molecular Cancer Therapeutics.

Aberrant Promoter Methylation of Sparc in Ovarian Cancer 1 , 2

S. Mok, J. Kwong, N. Said, 2014 .

Aberrant promoter methylation of SPARC in ovarian cancer.

S. Mok, J. Kwong, N. Said, 2009, Neoplasia.

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.

Patrick Soon-Shiong, Michael Hawkins, Leslie Louie, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel

A. Sparreboom, N. Desai, M. Acharya, 2005, Cancer biology & therapy.

539 Comparative pharmacokinetic (PK) study of a cremophor-free, protein stabilized, nanoparticle formulation (ABI-007) and a cremophor-based formulation of paclitaxel (P) in patients with advanced solid tumors

L. Harris, P. Soon-Shiong, N. Desai, 2004 .

Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

Michael Hawkins, William D. Figg, Paul J. Williams, 2005, Clinical Cancer Research.

Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL–Based Paclitaxel

R. Kerbel, Y. Shaked, Christina R. Lee, 2006, Clinical Cancer Research.

Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.

M. Flister, S. Ran, N. Desai, 2008, Neoplasia.

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.

Neil Desai, D. V. Von Hoff, E. Hersh, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nab-028, a nanoparticle albumin-bound novel taxane, shows improved efficacy and lower toxicity over the tween formulation (Tween-028)

J. Veith, P. Soon-Shiong, N. Desai, 2005 .

Abraxane (ABI-007) vs taxotere: a preclinical comparison of toxicity and efficacy

P. Soon-Shiong, N. Desai, V. Trieu, 2005 .

Surface-immobilized polyethylene oxide for bacterial repellence.

J. Hubbell, N. Desai, S. Hossainy, 1992, Biomaterials.

Molecular mass distribution of sodium alginate by high-performance size-exclusion chromatography.

P. Soon-Shiong, N. Desai, N. Ron, 1999, Journal of chromatography. A.

Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.

Brian Samuels, Neil Desai, G. Hortobagyi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of neoadjuvant bevacizumab and trastuzumab administered with albumin-bound paclitaxel (nab paclitaxel) and carboplatin in HER2+ locally advanced breast cancer

D. Yardley, N. Desai, V. Trieu, 2008 .

GELS FOR ENCAPSULATION OF BIOLOGICAL MATERIALS

N. Desai, S. Hossainy, 2017 .

Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).

K. Blackwell, P. Marcom, G. Kimmick, 2010 .

ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.

D. Kwiatkowski, R. Riedel, K. Ganjoo, 2019, Journal of Clinical Oncology.

Nanoparticle albumin bound (nab) technology: targeting tumors through the endothelial gp60 receptor and SPARC

N. Desai, 2007 .

Systemic Nanoparticle Paclitaxel (nab‐Paclitaxel) for In‐stent Restenosis I (SNAPIST‐I): A First‐in‐Human Safety and Dose‐finding Study

James Margolis, Richard Heuser, Renu Virmani, 2007, Clinical cardiology.

Polymeric shells for medical imaging prepared from synthetic polymers, and methods for the use thereof

K. Suslick, M. Grinstaff, P. Soon-Shiong, 1996 .

Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell

K. Suslick, M. Grinstaff, P. Soon-Shiong, 1995 .

Anti-angiogenic and antitumor activity of nanoparticle albumin bound (nab) thiocolchicine dimer (IDN5404) with a novel dual mechanism of action on Tubulin and Topoisomerase-1

P. Soon-Shiong, N. Desai, V. Trieu, 2006 .

A novel nanoparticle albumin bound thiocolchicine dimer (nab-5404) with dual mechanisms of action on tubulin and topoisomerase-1: evaluation of in vitro and in vivo activity

C. Manzotti, B. Kennedy, J. Veith, 2005 .

SPARC and CA19–9 as biomarkers in patients with advanced pancreatic cancer treated with nab paclitaxel plus gemcitabine

M. Hidalgo, M. Borad, L. Smith, 2008 .

Sustained Reduction of In-Stent Neointimal Growth With the Use of a Novel Systemic Nanoparticle Paclitaxel

R. Virmani, F. Kolodgie, M. John, 2002, Circulation.

Characterization and in vitro/in vivo dissolution of nab-paclitaxel nanoparticles

N. Desai, V. Trieu, T. De, 2008 .

Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT.

D. Kwiatkowski, R. Riedel, K. Ganjoo, 2020 .

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

W. Gradishar, P. Soon-Shiong, N. Desai, 2008, Anti-cancer drugs.

Challenges in Development of Nanoparticle-Based Therapeutics

Neil Desai, N. Desai, 2012, The AAPS Journal.

HER2 and SPARC status in tumors may play an important role in the relative effectiveness of nanoparticle albumin-bound (nab(r)) paclitaxel versus polysorbate-based docetaxel

W. Gradishar, P. Soon-Shiong, N. Desai, 2008 .

505 POSTER Improved effectiveness of nab-paclitaxel versus docetaxel in various xenografts as a function of HER2 and SPARC status

P. Soon-Shiong, N. Desai, V. Trieu, 2006 .